Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study
Open Access
- 23 March 2012
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 2 (3) , e62
Abstract
Bisphosphonates (BPs) are used intravenously to treat cancer-related conditions for the prevention of pathological fractures. Osteonecrosis of the jaw (BRONJ) is a rare complication reported in 4–15% of patients. We studied, retrospectively, 55 patients with multiple myeloma or Waldenstrom's macroglobulinemia followed up from different haematological departments who developed BRONJ. All patients were treated with BPs for bone lesions and/or fractures. The most common trigger for BRONJ was dental alveolar surgery. After a median observation of 26 months, no death caused by BRONJ complication was reported. In all, 51 patients were treated with antibiotic therapy, and in 6 patients, this was performed in association with surgical debridement of necrotic bone, in 16 with hyperbaric O2 therapy/ozonotherapy and curettage and in 12 with sequestrectomy and O2/hyperbaric therapy. Complete response was observed in 20 cases, partial response in 21, unchanged in 9 and worsening in 3. The association of surgical treatment with antibiotic therapy seems to be more effective in eradicating the necrotic bone than antibiotic treatment alone. O2 hyperbaric/ozonotherapy is a very effective treatment. The cumulative dosage of BPs is important for the evolution of BRONJ. Because the most common trigger for BRONJ was dental extractions, all patients, before BP treatment, must achieve an optimal periodontal health.Keywords
This publication has 35 references indexed in Scilit:
- The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkAnnals of Oncology, 2009
- Natural History of Osteonecrosis of the Jaw in Patients With Multiple MyelomaJournal of Clinical Oncology, 2008
- Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolutionSupportive Care in Cancer, 2008
- Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonatesLeukemia & Lymphoma, 2008
- The dilemma of jaw osteonecrosis in patients with multiple myeloma.Leukemia & Lymphoma, 2008
- Bisphosphonate Complications Including Osteonecrosis of the JawHematology-American Society Hematology Education Program, 2006
- Osteoclast Responses to Lipopolysaccharide, Parathyroid Hormone and Bisphosphonates in Neonatal Murine Calvaria Analyzed by Laser Scanning Confocal MicroscopyJournal of Histochemistry & Cytochemistry, 2005
- Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myelomaLeukemia, 2005
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Comparative Tolerability of Drug Therapies for Hypercalcaemia of MalignancyDrug Safety, 1999